Loading
A phase 2 trial of Cyclophosphamide, Pembrolizumab in ovarian cancer and hepatocellular carcinoma, run by ImmunoVaccine Technologies, Inc. (IMV Inc.), active and no longer recruiting.
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors is a phase 2 interventional study registered as NCT03836352 by ImmunoVaccine Technologies, Inc. (IMV Inc.), with 184 participants planned, started 2018-12-21 and due to reach its primary completion in 2023-12-31. Interventions recorded: DPX-Survivac, Cyclophosphamide, Pembrolizumab. Conditions listed: Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer. No results are recorded here; the registry entry is the source.